These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 6716396)
41. Calculation of drug-melanin binding energy using molecular modeling. Raghavan PR; Zane PA; Tripp SL Experientia; 1990 Jan; 46(1):77-80. PubMed ID: 2298284 [TBL] [Abstract][Full Text] [Related]
42. Fractional description of free energies of solvation. Luque FJ; Barril X; Orozco M J Comput Aided Mol Des; 1999 Mar; 13(2):139-52. PubMed ID: 10091120 [TBL] [Abstract][Full Text] [Related]
43. Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. Lapinsh M; Prusis P; Gutcaits A; Lundstedt T; Wikberg JE Biochim Biophys Acta; 2001 Feb; 1525(1-2):180-90. PubMed ID: 11342268 [TBL] [Abstract][Full Text] [Related]
44. Confounding variables in neuroendocrine challenge tests: what we need to control for. Golden RN; Gilmore JH; Ekstrom RD; Leatherman M; Carson SW Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():210A-211A. PubMed ID: 1498815 [No Abstract] [Full Text] [Related]
45. Interactions of drug sof abuse: preface. Vessell ES; Braude MC Ann N Y Acad Sci; 1976; 281():VII-X. PubMed ID: 1071362 [No Abstract] [Full Text] [Related]
46. [Drugs and the aged]. Platt D Med Monatsschr Pharm; 1983 Sep; 6(9):269-74. PubMed ID: 6633421 [No Abstract] [Full Text] [Related]
47. Molecular electrostatic potential as a factor of drug-receptor recognition. Dukhovich FS; Darkhovskii MB J Mol Recognit; 2003; 16(4):191-202. PubMed ID: 12898669 [TBL] [Abstract][Full Text] [Related]
48. [The rational computer-aided design of new drugs: a review of the methods]. Ivanov AS; Liul'kin IuA; Skvortsov VS; Rumiantsev AB Vestn Ross Akad Med Nauk; 1995; (12):51-6. PubMed ID: 8664605 [TBL] [Abstract][Full Text] [Related]
49. [Drugs: molecular pharmacology, sites of action and drug receptors]. Astier A Soins; 1984 Oct; (439):13-25. PubMed ID: 6569695 [No Abstract] [Full Text] [Related]
51. Binding of tracizolines to the imidazoline receptor. Role of lipophilicity in quantitative structure-activity relationship models. Pigini M; Bousquet P; Brasili L; Carrieri A; Dontenwill M; Gentili F; Giannella M; Leonetti F; Piergentili A; Quaglia W; Carotti A Ann N Y Acad Sci; 1999 Jun; 881():118-22. PubMed ID: 10415907 [No Abstract] [Full Text] [Related]
55. Modeling and simulation in molecular pharmacology. Mihalas GI; Kygyosi A; Lungeanu D; Vernic C Stud Health Technol Inform; 1998; 52 Pt 1():372-5. PubMed ID: 10384481 [TBL] [Abstract][Full Text] [Related]
56. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development. Rajamani R; Good AC Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857 [TBL] [Abstract][Full Text] [Related]
57. Computational modeling approaches to quantitative structure-binding kinetics relationships in drug discovery. De Benedetti PG; Fanelli F Drug Discov Today; 2018 Jul; 23(7):1396-1406. PubMed ID: 29574212 [TBL] [Abstract][Full Text] [Related]
58. Spectroscopic techniques for the study of drug interactions with biological systems. Chignell CF Adv Drug Res; 1970; 5():55-94. PubMed ID: 4321707 [No Abstract] [Full Text] [Related]
59. [Data for the modeling of drug-receptor interaction, taking into consideration additives or combined active ingredients in the formulation]. Bozzay J; Békefi E; Dávid A; Rusznák I Acta Pharm Hung; 1983 May; 53(3):97-105. PubMed ID: 6880768 [No Abstract] [Full Text] [Related]
60. I. Dissociation free energies of drug-receptor systems via non-equilibrium alchemical simulations: a theoretical framework. Procacci P Phys Chem Chem Phys; 2016 Jun; 18(22):14991-5004. PubMed ID: 27193067 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]